Chum Hospital Notre Dame

Montreal, Quebec H2X3E4

0 studies enrolling now · 7 studies all time

What they study most

Aneurysmal Subarachnoid Hemorrhage, Breast Cancer, Breast Neoplasms, Head and Neck Cancer, Metastatic Bladder Cancer, Multiple Sclerosis, Relapsing-Remitting, Prostate Cancer, Urinary Tract Neoplasms, Urologic Neoplasms

Studies at this site

• Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck — Running, not enrolling
• A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer — Completed
• Clazosentan in Aneurysmal Subarachnoid Hemorrhage — Stopped early
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer — Completed
• A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer — Completed
• Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis — Completed
• Trial of Myocet in Metastatic Breast Cancer — Status unconfirmed